Acurable, a London-based award-winning wearable medical devices company, has secured an additional £9.5m (€11m) investment in Series A funding.
The investment was led by Kibo Ventures, along with Mundi Ventures, Kindred Capital, and Comprador Holdings among others.
The funding will be used to accelerate the international expansion of its first product AcuPebble SA100 and drive the company towards its ambition to become the preferred solution for home sleep testing worldwide.
After successfully launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.
AcuPebble SA100 is the first wearable medical device to obtain a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home, and has received FDA 510(k) clearance in the US.
Acurable’s international expansion brings it one step closer to solving the current unmet needs in diagnosis and monitoring of OSA – a significant issue affecting approximately one billion people globally.1
Co-CEO Professor Esther Rodriguez-Villegas, inventor of the AcuPebble technology, said: “The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world.
“This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions.”
Sonia Fernández, partner at Kibo Ventures,* said: “AcuPebble has the potential to transform the way sleep apnoea and other chronic conditions are diagnosed and monitored. It’s much more accurate and easier to use than other devices, and we believe it’s a huge step forward for global healthcare. This is still just the beginning for Acurable and I cannot wait for what comes next.”
Acurable was founded in 2016 and has offices in London and Seville.